This protocol applies to men with impotence of organic origin who were previously treated with an oral phosphodiesterase type 5 (PDE5) inhibitor and did not achieve erections sufficient for satisfactory sexual performance.
The prior treatment line — an FDA-approved oral PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil), titrated to provide optimal efficacy — did not achieve the goal of a penile erection sufficient for satisfactory sexual performance. Failure to meet that target triggers escalation to this next structured protocol.
DOI: 10.1016/j.juro.2018.05.004
Men with ED should be informed regarding the treatment option of a vacuum erection device (VED), including discussion of benefits and risks/burdens.
Men with ED should be informed regarding the treatment option of intraurethral (IU) alprostadil, including discussion of benefits and risks/burdens.
Intraurethral (IU) medication involves the insertion of a delivery catheter into the meatus and depositing an alprostadil (prostaglandin E1) pellet in the urethra to induce an erection sufficient for intercourse.
Men with ED should be informed regarding the treatment option of intracavernosal injections (ICI), including discussion of benefits and risks/burdens.
ICI medications are administered by injecting alprostadil, papaverine, phentolamine, and/or atropine into the corpus cavernosum of the penis to produce an erection.
The most commonly used outcome measure in ICI studies is the percentage of men who reported achieving an erection sufficient for successful intercourse.
View source ↗